A detailed history of Us Bancorp \De\ transactions in Legend Biotech Corp stock. As of the latest transaction made, Us Bancorp \De\ holds 4,976 shares of LEGN stock, worth $220,387. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,976
Previous 11,255 55.79%
Holding current value
$220,387
Previous $498,000 51.41%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$43.55 - $59.88 $273,450 - $375,986
-6,279 Reduced 55.79%
4,976 $242,000
Q2 2024

Aug 06, 2024

BUY
$39.5 - $57.22 $174,590 - $252,912
4,420 Added 64.67%
11,255 $498,000
Q1 2024

May 07, 2024

BUY
$55.06 - $69.99 $16,132 - $20,507
293 Added 4.48%
6,835 $383,000
Q4 2023

Feb 09, 2024

SELL
$57.25 - $69.74 $117,763 - $143,455
-2,057 Reduced 23.92%
6,542 $393,000
Q3 2023

Nov 03, 2023

SELL
$63.16 - $76.5 $26,590 - $32,206
-421 Reduced 4.67%
8,599 $577,000
Q2 2023

Aug 09, 2023

SELL
$46.28 - $75.01 $224,874 - $364,473
-4,859 Reduced 35.01%
9,020 $622,000
Q1 2023

May 09, 2023

BUY
$43.42 - $57.37 $35,213 - $46,527
811 Added 6.21%
13,879 $669,000
Q4 2022

Feb 13, 2023

BUY
$38.8 - $55.46 $493,070 - $704,785
12,708 Added 3530.0%
13,068 $652,000
Q3 2022

Oct 27, 2022

BUY
$38.15 - $57.1 $4,501 - $6,737
118 Added 48.76%
360 $15,000
Q1 2022

May 11, 2022

BUY
$31.02 - $48.18 $4,963 - $7,708
160 Added 195.12%
242 $9,000
Q4 2021

Feb 11, 2022

SELL
$41.14 - $56.98 $10,285 - $14,245
-250 Reduced 75.3%
82 $4,000
Q3 2021

Nov 10, 2021

BUY
$35.31 - $50.56 $11,722 - $16,785
332 New
332 $17,000

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $7.41B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Us Bancorp \De\ Portfolio

Follow Us Bancorp \De\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.